Skip to content

XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Coronavirus – COVID-19 Program
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Presentations
    • Media
    • Independent Research
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search

Hypertension References

  1. Chobanian AV, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289:2560-72.
  2. Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. Circulation 2000; 101:329-35.
  3. Fieg DL. The Role of Uric Acid in the Pathogenesis of Hypertension in the Young. The Journal of Clinical Hypertension 2012; 14:346-352.
  4. Feig DL, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension 2003; 42:247-52.
  5. Grayson PC, et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res. 2011; 63:102–110.
  6. Soletsky B, Fieg DL.  Uric acid reduction rectifies prehypertension in obese adolescents.  Hypertension 2012; 60:1148-1156.
  7. Feig DL, Soletsky B, Johnson RJ.  Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.  JAMA 2008; 300:924-932.
  8. Roger VL, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012; 125(1):e2–220.
  9. McNiece KL, et al. Prevalence of hypertension and prehypertension among adolescents. J. Pediatr. 2007; 150:640-4.
  10. Sorof JM, et al. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics 2004; 113: 475-82.
  11. Hansen ML, et al. Underdiagnosis of hypertension in children and adolescents. JAMA 2007; 298: 874-9.
  12. Williams, B, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. Journal of Human Hypertension 2004; 18:139–85.
  13. NPS Prescribing Practice Review 52: Treating hypertension. NPS Medicines Wise. September 1, 2010.
  14. Siebenhofer, A, et al. Long-term effects of weight-reducing diets in hypertensive patients. Cochrane Database of Systematic Reviews 2004; Issue 9. 
  15. Blumenthal JA, et al. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. Arch. Intern. Med. 2010; 170:126-35.
  16. He, FJ, MacGregor, GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database of Systematic Reviews 2004; Issue 3.
  17. Your guide to lowering blood pressure with DASH.  NIH Publication No. 06-4082, 2006.
  18. Law M, et al. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess 2003; 7:1-94.
  19. Nelson, Mark. Drug treatment of elevated blood pressure. Australian Prescriber 2010; 33:108-112.
  20. Shaw, Gina. Prehypertension: Early-stage High Blood Pressure”. WebMD. http://www.webmd.com/hypertension-high-blood-pressure/features/new-low-for-high-blood-pressure. Retrieved 2012-12-12.
  21. Mancia G, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J. Hypertens. 2007; 25:1751-62.

Press Releases

  • XORTX Grants Options January 12, 2021
  • XORTX Announces Private Placement January 7, 2021
  • XORTX Announces Private Placement January 7, 2021
  • XORTX Announces Grant of European Patent December 29, 2020
  • XORTX Announces Topline Results from Mount Sinai’s COVID-19 Clinical Study November 16, 2020
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress